Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1680-1688

  Fowble, Barbara ^a   Hanlon, Alexandra ^a   Freedman, Gary ^a   Patchefsky, Art ^a   Kessler, Howard ^a   Nicolaou, Nicos ^a   Hoffman, John ^a   Sigurdson, Elin ^a   Boraas, Marcia ^a   Goldstein, Lori ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 0033037074     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1680     Document Type: Article

References (58)

1. Wiklund I, Bert G, Hammar M, et al: Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 14:225-236, 1992
2. Daly E, Gray A, Barlow D, et al: Measuring the impact of menopausal symptoms in quality of life. BMJ 307:836-840, 1993
3. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 20:47-63, 1991
4. Stampfer MJ, Colditz GA, Willett WC, et al: Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow up from the Nurses' Health Study. N Engl J Med 325:756-762, 1991
5. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265:1861-1867, 1991
6. Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037, 1992
7. Psaty BM, Heckbert SR, Atkins D, et al: The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women. Arch Intern Med 154:1333-1339, 1994
8. Falkeborn M, Persson I, Adami HO, et al: The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 99:821-828, 1992
9. Henderson BE, Paganini-Hill A, Ross RK: Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 159:312-317, 1988
10. Grodstein F, Stampfer MJ, Manson JE, et al: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335:453-461, 1996
11. Colditz GA, Willett WC, Stampfer MJ, et al: Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105-1110, 1987
12. Lobo BA: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73:925-931, 1991
13. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273:199-208, 1995
14. Gambrell DR, Teran AZ: Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 165:307-317, 1991
15. Speroff L, Rowan J, Symons J, et al: The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): A randomized controlled trial. JAMA 276:1397-1403, 1996
16. The Writing Group for the PEPI Trial: Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trail. JAMA 276:1389-1396, 1996
17. Cauley JA, Seeley DG, Ensrud K, et al: Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16, 1995
18. Lufkin EG, Wahner HW, O'Fallon WM, et al: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9, 1992
19. Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75-78, 1991
20. Grodstein F, Stampfer MJ, Colditz GA, et al: Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1775, 1997
21. Schairer C, Adami H-O, Hoover R, et al: Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 8:59-65, 1997
22. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995
23. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047-1059, 1997
24. Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 168:1473-1480, 1993
25. Sillero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, et al: Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 29:286-294, 1992
26. Steinberg KK, Thacker SB, Smith SJ, et al: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990, 1991
27. Strickland DM, Gambrell RD Jr, Butzin CA, et al: The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 80:400-404, 1992
28. Gambrell RD Jr: Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol 150:119-132, 1984
29. Willis DB, Calle EE, Miracle-McMahill L, et al: Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449-457, 1996
30. Bergkvist L, Adami H-O, Persson I, et al: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130:221-228, 1989
31. Hunt K, Vessey M, McPherson K, et al: Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94:620-635, 1987
32. Hunt K, Vessey M, McPherson K: Mortality in a cohort of long term users of hormone replacement therapy: An update analysis. Br J Obstet Gynaecol 97:1080-1086, 1990
33. Persson I, Thurfjell E, Holmberg L: Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 15:3201-3207, 1997
34. Cyrlak D, Wong CH: Mammographic changes in postmenopausal women undergoing hormonal replacement therapy. AJR Am J Roentgenol 161:1177-1183, 1993
35. Laya MB, Larson EB, Taplin SH, et al: Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88:643-649, 1996
36. Wilson TE, Roubidoux MA, Orange R, et al: Estrogen replacement therapy and post menopausal women: Effect on positive predictive value of screening mammography. Presented at the 97th annual meeting of the American Roentgen Ray Society, Boston, MA, 1997
37. AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997
38. Armitage P: Statistical Methods of Medical Research. New York, NY, Wiley, 1973
39. Mehta CR, Patel HR: A network of algorithm for performing Fisher's exact test in R cross C contingency tables. J Am Stat Assoc 78:427-434, 1983
40. Lehmann EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden-Day, 1975
41. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
42. Kalbfleish JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
43. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
44. Mantel M: Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother Rep 50:163-170, 1966
45. Holli K, Isola J, Cuzick J: Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16:3115-3120, 1998
46. Magnusson C, Holmberg L, Norden T, et al: Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38:325-334, 1996
47. Cauley JA, Cummings SR, Black DM, et al: Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 163:1438-1444, 1990
48. Barrett-Connor E: Postmenopausal estrogen and prevention bias. Ann Intern Med 115:455-456, 1991
49. Colditz GA, Stampfer MJ, Willett WC, et al: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264:2648-2653, 1990
50. Bonnier P, Romain S, Giacalone PL, et al: Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85:11-17, 1995
51. Squitieri R, Tartter PI, Ahmed S, et al: Carcinoma in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 178:167-170, 1994
52. Harding C, Knox WF, Faragher EB, et al: Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit. BMJ 312:1646-1647, 1996
53. Salmon RJ, Remvikos Y, Ansquer Y, et al: HRT and breast cancer. Lancet 346:1702-1703, 1995
54. Lower EE, Blau R, Gazder P, et al: Exogenous estrogen usage is associated with estrogen receptor positive breast cancers. Breast Cancer Res Treat 37:64, 1996 (abstr)
55. Yuen J, Persson I, Bergkvist L, et al: Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for "healthy drug-user" effect. Cancer Causes Control 4:369-374, 1993
56. Grodstein F, Martinez ME, Giovannucci EL, et al: Postmenopausal hormone use and colorectal cancer in the Nurses' Health Study. Am J Epidemiol 143:S63, 1996 (abstr)
57. Calle EE, Miracle-McMahill HL, Thun MJ, et al: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87:517-523, 1995
58. Newcomb PA, Storer BE: Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 87:1067-1071, 1995